<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00330343</url>
  </required_header>
  <id_info>
    <org_study_id>04-03-31-02</org_study_id>
    <nct_id>NCT00330343</nct_id>
  </id_info>
  <brief_title>Optimal Dose of Prophylactic Naloxone in Reducing Opioid-Induced Side Effects in Children/Adolescents</brief_title>
  <official_title>The Optimal Dose of Prophylactic Naloxone in Ameliorating Opioid Induced Side Effects in Children and Adolescents Receiving Intravenous Patient Controlled Analgesia (IVPCA) Morphine for Moderate to Severe Pain: A Pharmacodynamic, Pharmacokinetic, and Pharmacogenetic Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an investigator initiated dose finding study designed to determine the optimal dose
      of naloxone to prevent or minimize the most common side effects induced by opioids, namely
      itching, nausea, and vomiting. Male and female inpatients of the Children's Center of the
      Johns Hopkins Hospital, who are greater than 6 and less than 18 years of age with acute,
      moderate to severe pain, and who are to be treated with intravenous Patient controlled
      analgesia (IVPCA) morphine will be eligible for inclusion in this study. Patients will be
      recruited by a study investigator prior to the initiation of IVPCA therapy. The majority of
      patients will be post operative patients, and will start therapy and the investigational drug
      in the Post Anesthesia Care Unit or the Pediatric Intensive Care Unit. The investigators plan
      on studying between 10 and 99, male and female patients over a 2 year period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients of all ages, opioids are the cornerstone of management of moderate to severe
      pain. Regardless of method of administration, all opioids produce unwanted side effects,
      including pruritus, nausea and vomiting, constipation, urinary retention, cognitive
      impairment, tolerance, dependence, and (rarely) respiratory depression. Based on the results
      of a previously completed randomized controlled trial, children and adolescents with moderate
      to severe pain, are now routinely treated in the Children's Center of the Johns Hopkins
      Hospital with a low dose naloxone infusion (0.25 mcg/kg/HOUR) whenever morphine intravenous
      patient controlled analgesia (IVPCA) or parent/nurse controlled analgesia (IVPNCA) is
      initiated. Although the previous study showed a marked reduction in the incidence and
      severity of pruritus and nausea, approximately a third of the patients still experience these
      side effects. The primary purpose of this study is to reduce this failure rate by determining
      if there is an optimal dose of naloxone to prevent opioid induced side effects as determined
      by a dose finding classic up down dose escalation method. The second aim is to determine the
      pharmacokinetics of morphine and naloxone and their metabolites at each of the naloxone
      infusion rates attempted. The investigators will measure morphine, naloxone, and their
      metabolites using a liquid chromatographic-electrospray ionization-tandem mass spectrometric
      method (LC/MS/MS). The final aim is to determine the pharmacogenetics of responders and
      non-responders using DNA isolated from patient blood. To accomplish this the investigators
      will need a single blood collection from patients currently being treated with IVPCA morphine
      and low dose intravenous naloxone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Naloxone Side Effects</measure>
    <time_frame>0-48 hours after infusion begins</time_frame>
    <description>incidence of nausea, vomiting, pruritus following naloxone infusion</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Pain</condition>
  <condition>Nausea</condition>
  <condition>Pruritus</condition>
  <arm_group>
    <arm_group_label>Naloxone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>continuous infusion of naloxone administered in escalating dosing from 0.05 mcg/kg/hr to 1.65 mcg/kg/hour</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>naloxone</intervention_name>
    <description>continuous infusion of naloxone administered in escalating dosing from 0.05 mcg/kg/hr to 1.65 mcg/kg/hour</description>
    <arm_group_label>Naloxone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female patients greater than 6 and less than 18 years of age with acute,
             moderate to severe pain who are to start treatment with IVPCA morphine as inpatients
             of the Children's Center of the Johns Hopkins Hospital

        Exclusion Criteria:

          -  patients who require concomitant benzodiazepine administration

          -  allergic to opioids

          -  have been in an investigational drug trial within 1 month

          -  received opioids with in 7 days of the study

          -  parent with psychiatric illness which impairs their ability to provide consent parent
             who does not speak English
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myron Yaster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>John Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Maxwell LG, Kaufmann SC, Bitzer S, Jackson EV Jr, McGready J, Kost-Byerly S, Kozlowski L, Rothman SK, Yaster M. The effects of a small-dose naloxone infusion on opioid-induced side effects and analgesia in children and adolescents treated with intravenous patient-controlled analgesia: a double-blind, prospective, randomized, controlled study. Anesth Analg. 2005 Apr;100(4):953-8.</citation>
    <PMID>15781505</PMID>
  </reference>
  <reference>
    <citation>Gan TJ, Ginsberg B, Glass PS, Fortney J, Jhaveri R, Perno R. Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate. Anesthesiology. 1997 Nov;87(5):1075-81.</citation>
    <PMID>9366459</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2006</study_first_submitted>
  <study_first_submitted_qc>May 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2006</study_first_posted>
  <results_first_submitted>April 10, 2012</results_first_submitted>
  <results_first_submitted_qc>July 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 19, 2017</results_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>morphine</keyword>
  <keyword>naloxone</keyword>
  <keyword>pediatrics</keyword>
  <keyword>adverse effects</keyword>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pruritus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>75 participants were consented, but only 64 participants participated in this study and were placed in the experimental arm.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Naloxone</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Naloxone Side Effects</title>
        <description>incidence of nausea, vomiting, pruritus following naloxone infusion</description>
        <time_frame>0-48 hours after infusion begins</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Naloxone</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Naloxone Side Effects</title>
          <description>incidence of nausea, vomiting, pruritus following naloxone infusion</description>
          <units>participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32" lower_limit="10" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea, Vomiting or pruritis</sub_title>
                <description>Nausea, vomiting, or pruritis</description>
                <counts group_id="E1" events="59" subjects_affected="32" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Myron Yaster</name_or_title>
      <organization>JHU</organization>
      <phone>9552393</phone>
      <email>myaster1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

